Article Details

Phase 1 Study of Potential IPF Therapy, PLN-74809, Doses 1st Group, Pliant Says

Retrieved on: 2019-01-08 21:29:47

Tags for this article:

Click the tags to see associated articles and topics

Phase 1 Study of Potential IPF Therapy, PLN-74809, Doses 1st Group, Pliant Says. View article details on hiswai:

Excerpt

<div>Pliant Therapeutics, a California-based company, was launched in 2016 following a financing round of $45 million raised by <b>Third Rock Ventures</b>.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo